Therefore TNF-α antagonists (adalimumab, infliximab, and etanercept) were approved by the US Federal Drug and Administration (FDA) for the treatment of psoriasis and rheumatic arthritis [53,54,55,56]. The gene discussed is TNF; the disease is psoriasis.